Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported.
The review covers Beyfortus (from Sanofi and AstraZeneca) and Enflonsia (from Merck), both monoclonal antibodies that help shield babies from respiratory syncytial virus, or RSV.
The move comes as several immunizations have faced new scrutiny under U.S. Health Secretary Robert F. Kennedy Jr.
The U.S. Food and Drug Administration said it is taking a close look at all available data, as it does with any approved product.
Related
